Boston halts drug-eluting stent trial
This article was originally published in Clinica
Executive Summary
Boston Scientific has halted the further enrolment of patients in a European clinical trial of a drug-coated coronary stent for reducing restenosis. The move comes after researchers reported an "unacceptable" rate of major adverse events in some of the patients implanted with the device.